182CYP2D6 as an Emerging Endogenous Oxidative Stress Modulator in Cardiovascular Disease: Genetic, Pharmacological, and Redox Perspectives.2026 · Europe PMC
183Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.2026 · Europe PMC
184Progress on the regulation of colorectal cancer and cardio-oncology by the gut microbiota and nutrients.2026 · Europe PMC
185Physical activity and cardiorespiratory fitness in atherosclerotic cardiovascular disease risk prediction: integrating digital phenotyping, mechanistic insights, and multimodal clinical prediction for actionable stratification.2026 · Europe PMC
186Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.2026 · Europe PMC
189TAMIS Consensus on Multidisciplinary Team Care in Post-Acute Stage of Acute Coronary Syndrome: Nutrition, Pharmacotherapy, and Cardiac Rehabilitation.2026 · Europe PMC
190How to prevent missing data in cost-effectiveness analyses alongside cardiovascular disease trials? A review on methods of administration of patient-reported outcomes.2026 · Europe PMC
191Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.2026 · Europe PMC
192Bidirectional brain-heart communication in coronary heart disease: from coronary plaques to central autonomic networks.2026 · Europe PMC
193Association of testosterone and testosterone replacement therapy with atrial fibrillation: an updated review.2026 · Europe PMC
194Meta-Analysis of SGLT2 Inhibitors in Transthyretin Cardiac Amyloidosis: Insights by Disease-Modifying Therapy.2026 · Europe PMC
196Special Issue "Exercise Training on Cardiovascular Risk Factors in Primary and Secondary Prevention".2026 · Europe PMC
197Melatonin supplementation, hyperprolactinemia, and incident heart failure: A proposed prolactin-mediated pathway for cardiovascular risk.2026 · Europe PMC
198Prophylactic implantation of implantable cardioverter-defibrillator for the primary prevention of sudden cardiac death after myocardial infarction: protocol for systematic review and meta-analysis of randomised controlled trials.2026 · Europe PMC
199Positron emission tomography imaging of T-cell activity in cardiovascular disease and its emerging role in imaging adaptive immunity.2026 · Europe PMC
200Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data.2026 · Europe PMC
201Trimetazidine in Chronic Coronary Syndrome and Coronary Artery Disease: A Narrative Review of Clinical Efficacy, Safety, and Current Guideline Position.2026 · Europe PMC
202Rehabilitation for Cardiorenal Multimorbidity: Epidemiology, Functional Phenotypes, and Effects on Physical Function, Renal Trajectory, and Prognosis.2026 · Europe PMC
203Understanding the distinct role of PI3K(p110<i>α</i>) in cancer and the heart to prevent chemotherapy-induced cardiotoxicity: mechanisms and therapeutic opportunities.2026 · Europe PMC
204Mapping the Inflammation Research Landscape in Myocardial Infarction, 1995-2025: A Bibliometric Analysis of WoSCC and PubMed.2026 · Europe PMC
205Distinct mechanistic features of atrial fibrillation in hypertrophic cardiomyopathy.2026 · Europe PMC
206Subclinical Inflammation in Ischemic Heart Disease and Its Role in the Transition to Heart Failure.2026 · Europe PMC
207Diabetic kidney disease within the framework of cardio-kidney-metabolic health: a paradigm shift.2026 · Europe PMC
208Gut microbiota-derived metabolites in cardiovascular disease: mechanisms, disease-specific roles, and translational opportunities.2026 · Europe PMC
209Management of dyslipidaemia in patients with comorbidities-facing the challenge: heart failure.2026 · Europe PMC
210The growing need for heart failure specific risk prediction models and standardized care pathways in patients with cancer.2026 · Europe PMC
211Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?2026 · Europe PMC
212Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?2026 · Europe PMC
213Understanding Exercise-induced Protection in Heart Failure with Reduced Ejection Fraction and Heart Failure with Preserved Ejection Fraction: Molecular Mechanisms and New Therapeutic Opportunities.2026 · Europe PMC
214Across Clinical Profiles of Cardiorenal–Metabolic (CKM) Syndrome: A Phenotype-Driven Therapeutic Approach2026 · Europe PMC
215Effect of fish oil as an adjunct therapy to metformin on vascular and cardiac health in women with polyendocrine metabolic ovarian syndrome: protocol for a randomised, placebo-controlled clinical trial.2026 · Europe PMC
216Endothelial Injury as a Potential Contributor to Cardiovascular Toxicity in Hematologic Malignancies.2026 · Europe PMC
218Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease.2026 · Europe PMC
219The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory Mechanisms and Clinical Utility.2026 · Europe PMC
220Myeloid-Derived Suppressor Cells (MDSCs) in Cardiovascular Risk of Obesity-Associated Diabetes.2026 · Europe PMC
221Effects of Continuous Positive Airway Pressure on Surrogate, Intermediate, and Functional Cardiovascular Outcomes in Obstructive Sleep Apnea: An Umbrella Review of Systematic Reviews and Meta-Analyses.2026 · Europe PMC
223Gut microbiota-bile acid axis in cardiovascular disease: a spatiotemporal framework for predictive, preventive and personalised medicine.2026 · Europe PMC
224The Gut-Heart Axis in Cardiovascular Disease: Microbial Metabolites, Mediterranean and Traditional Turkish Dietary Patterns, and Personalized Medicine.2026 · Europe PMC
225Beta-Blocker Use After Acute Myocardial Infarction: Differential Impact Across Heart Failure Subtypes in a Real-World Cohort.2026 · Europe PMC
226Heart Failure With Preserved Ejection Fraction: A Practical, Stepwise Guide to Evidence-Based Therapy in 2026.2026 · Europe PMC
227Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.2026 · Europe PMC
228Influence of Fitness on Exercise Blood Pressure and Cardiac Structure: Data from the Exercise Stress Test Collaboration (EXERTION).2026 · Europe PMC
230The gut-heart axis: a review of the mechanisms and therapeutic prospects of gut microbiota and their metabolites in cardiovascular disease.2026 · Europe PMC
231Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease: Gene-Specific Mechanisms and Therapeutic Implications.2026 · Europe PMC
232Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications.2026 · Europe PMC
233Study on blueberries, protein and exercise for improving frailty and cardiovascular disease (STRONG): protocol for a parallel-group randomised controlled superiority trial in older Nova Scotians.2026 · Europe PMC
234Balancing the autonomic scale: the promise of transcutaneous vagus nerve stimulation in combating cardiovascular diseases.2026 · Europe PMC
235Proresolving mediators as cardiovascular biomarkers: solo players or an orchestra?2026 · Europe PMC
237Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer - from feasibility to precision practice.2026 · Europe PMC
239Metabolic syndrome severity and the effects of intensive blood pressure lowering: Results from the STEP randomized trial.2026 · Europe PMC
240Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis.2026 · Europe PMC